Myriad genetics

MyRisk® with RiskScore®

Fact Sheet

MyRisk® with RiskScore® from Myriad Genetics is an all-in-one hereditary cancer test, risk assessment, and care plan. For patients with family history of certain cancers, hereditary cancer testing is the primary way to determine if they are at an increased risk of developing specific types of cancer.

MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides each patient with a breast cancer risk assessment individualized to them.

Guides medical management decisions

Because of the precision science behind MyRisk, 53% of patients[1] qualify for a medical management change that may help lower cancer risk, as opposed to only 10%[2] with other hereditary cancer tests.

Delivers personalized care plans

The MyRisk Management Tool offers personalized guidance for patients and providers to work together to help reduce risk of developing cancer or detect it at an earlier, more treatable stage.

Gives a precise answer about breast cancer risk

As the first and only comprehensive breast cancer risk assessment validated for all eligible patients[3], the RiskScore component of MyRisk gives patients both a five-year and remaining lifetime risk estimate of developing breast cancer. This is calculated using a combination of clinical risk factors, family history, and unique genetic breast cancer risk markers.

---

[1] Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
[2] American Cancer Society. Family Cancer Syndromes. https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes.html. Accessed September 2023
[3] Eligible patients include women ages 18-85 who have no personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy with unknown results, and is negative for a breast cancer related gene mutation.

Support every step of the way
Myriad Genetics supports patients and healthcare providers throughout the genetic screening process, with pre-test education, billing support, clear results reporting, and post-test consultations. These supporting services allow for simple integration of Myriad Genetics' genetic screens into routine clinical care and help patients better understand and benefit from their test results.

Making genetic insights affordable for everybody
Myriad Genetics is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.[4]

- More than 90% of patients tested with MyRisk pay $0 out-of-pocket
- 60% of patients are eligible for financial assistance
- 95% of private insurers have coverage for testing
- For patients who do not meet criteria, have a high unmet deductible, or are uninsured Myriad Genetics offers an affordable direct pay price

[4] Myriad Internal Data Based on OBGYN & Primary Care setting. Last Updated 2023